Bain leads $150M round to push blind­ness biotech's rare dis­ease drug to­ward FDA

Alkeus Phar­ma­ceu­ti­cals has raised $150 mil­lion via a Se­ries B round in or­der to ad­vance a pre­ci­sion med­i­cine can­di­date to treat Star­gardt dis­ease, a cur­rent­ly in­cur­able ge­net­ic dis­ease that caus­es blind­ness in chil­dren and young adults.

The news, an­nounced Mon­day, said that the fi­nanc­ing would go to­ward push­ing the drug can­di­date, gildeuretinol, to­wards the FDA and to NDA sub­mis­sion. The fi­nanc­ing will al­so be used to ex­pand the com­pa­ny — but ex­act specifics weren’t dis­closed.

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.

SIGN UP LOG IN BECOME A PREMIUM SUBSCRIBER